Literature DB >> 26637564

Dietary modifications for refractory chronic rhinosinusitis? Manipulating diet for the modulation of inflammation.

Smriti Nayan1, Alexandra Maby, Leandra Mfuna Endam, Martin Desrosiers.   

Abstract

BACKGROUND: An endotype of chronic rhinosinusitis (CRS) refractory to medical and surgical management is characterized by persistent T-helper 1/T-helper 17 inflammation of the sinus mucosa, which potentially facilitates colonization with dysbiotic microbial flora. Dietary interventions that target reduction of systemic inflammation are increasingly recommended as adjuncts to ongoing medical therapy in chronic disorders with a strong inflammatory component, such as cardiac disease, diabetes, and metabolic syndrome. Inflammation-reducing dietary modifications may thus be of benefit in patients with refractory CRS (RCRS).
OBJECTIVE: To identify nonpharmacologic approaches that implicate modification of dietary factors, potentially reducing systemic level of inflammation in RCRS.
METHODS: A systematic review of the literature was undertaken to identify dietary strategies for reducing inflammation in metabolic syndrome, diabetes, and cardiac disease. Mechanistic-based strategies for reducing systemic inflammation were identified and categorized to identify potential therapeutic avenues, which would be applicable to RCRS.
RESULTS: Principal mechanisms for altering inflammation at the systemic level via dietary manipulation center around (1) increased consumption of foods with anti-inflammatory properties, and (2) modulation of the gut microbiome to reduce short-chain fatty acid secretion by dysbiotic gut flora. Recommended dietary modifications to reduce systemic markers of inflammation or to improve RCRS include alteration of macronutrient intake, alterations in consumption of meat and fats, consumption of prebiotics and probiotics, and a low-salicylate diet in the context of aspirin-exacerbated respiratory disease.
CONCLUSION: Dietary modifications may offer a potential nonpharmacologic means of reducing inflammation in patients with RCRS and hence may represent a complementary adjunct to existing medical therapies. Additional prospective studies are required to further validate the concept of dietary modifications in patients with RCRS to support the findings.

Entities:  

Mesh:

Year:  2015        PMID: 26637564     DOI: 10.2500/ajra.2015.29.4220

Source DB:  PubMed          Journal:  Am J Rhinol Allergy        ISSN: 1945-8932            Impact factor:   2.467


  5 in total

Review 1.  A role for auto-immunity in chronic rhinosinusitis? Lessons learned from sub-epidermal bullous disorders of the skin.

Authors:  Philippe Lefrançois; Hugo Chapdelaine; Benoît Côté; Martin Desrosiers
Journal:  Allergy Asthma Clin Immunol       Date:  2016-08-05       Impact factor: 3.406

2.  Latest advances in chronic rhinosinusitis with nasal polyps endotyping and biomarkers, and their significance for daily practice.

Authors:  Alma Aurelia Maniu; Maria Ida Perde-Schrepler; Corina Bianca Tatomir; Mihai Ionuţ Tănase; Maximilian George Dindelegan; Vlad Andrei Budu; Gheorghe Doinel Rădeanu; Marcel Cosgarea; Carmen Aurelia Mogoantă
Journal:  Rom J Morphol Embryol       Date:  2020 Apr-Jun       Impact factor: 1.033

3.  Effect of low salicylate diet on clinical and inflammatory markers in patients with aspirin exacerbated respiratory disease - a randomized crossover trial.

Authors:  Leigh J Sowerby; Krupal B Patel; Crystal Schmerk; Brian W Rotenberg; Taciano Rocha; Doron D Sommer
Journal:  J Otolaryngol Head Neck Surg       Date:  2021-04-23

Review 4.  Influence of the Microbiome on Chronic Rhinosinusitis With and Without Polyps: An Evolving Discussion.

Authors:  Kyle S Huntley; Joshua Raber; Lauren Fine; Jonathan A Bernstein
Journal:  Front Allergy       Date:  2021-10-01

5.  Application of probiotics in adjuvant treatment of infant allergic rhinitis: A randomized controlled study.

Authors:  Xueqiu Cao; Ping Zhong; Gang Li; Jiao Zhu; Yun Zheng
Journal:  Medicine (Baltimore)       Date:  2020-05       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.